The drug – formerly known as SRP-5051 – is a more potent version of Exondys 51 (eteplirsen), an exon-skipping therapy that can be used to treat around 13% of the population with the muscle ...

Intronic primers flanking exon 9 were designed using the PAC sequence ... it may indicate that a specific underlying mutation mechanism exists. Finally, in addition to the obvious change at ...